Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3073525 | 0.87 | NAMPT (0.47) | KDM4EHSD17B10ALDH1A1LMNAUSP2 | |
| SCHEMBL6269623 | 0.87 | KDM4E (0.46) | KDM4EHSD17B10ALDH1A1LMNAUSP2 | |
| SCHEMBL3458409 | 0.80 | ALDH1A1 (0.63) | KDM4EALDH1A1ALOX15KMT2ADRD2 | |
| SCHEMBL7672874 | 0.79 | CHRNA7 (0.57) | ALDH1A1LMNADRD2DRD3CYP1A2 | |
| SCHEMBL3458346 | 0.77 | DRD2 (0.54) | ALDH1A1DRD2DRD3 | |
| SCHEMBL83163 | 0.74 | HTR1A (0.63) | DRD2DRD3 | |
| SCHEMBL3458647 | 0.74 | HTR2A (0.54) | KDM4EALDH1A1ALOX15DRD3CYP1A2 | |
| SCHEMBL3077208 | 0.74 | FNTA (0.47) | ALDH1A1DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL6482895 | 0.73 | FNTA (0.47) | ALDH1A1DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL6772828 | 0.72 | KMT2A (0.51) | KDM4EHSD17B10ALDH1A1LMNAUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4607319-B2 | — | — | 2011-01-05 | — | — | JP | claimed |
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-09-09 | — | — | US | claimed |
| EP-1079832-B1 | USE OF VITAMIN PP COMPOUNDS | KLINGE CO CHEM PHARM FAB (DE) | 2005-11-30 | — | — | EP | claimed |
| EP-1060163-B1 | NEW PIPERAZINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | KLINGE CO CHEM PHARM FAB (DE) | 2005-10-12 | — | — | EP | claimed |
| US-6903118-B1 | Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides | KLINGE PHARMA GMBH (DE) | 2005-06-07 | — | — | US | claimed |
| JP-2002512190-A | — | — | 2002-04-23 | — | — | JP | claimed |
| EP-1079832-A1 | USE OF VITAMIN PP COMPOUNDS | Klinge Pharma GmbH (DE) | 2001-03-07 | — | — | EP | claimed |
| EP-1060163-A1 | NEW PIPERAZINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | Klinge Pharma GmbH (DE) | 2000-12-20 | — | — | EP | claimed |
| WO-1999053920-A1 | USE OF VITAMIN PP COMPOUNDS | KLINGE PHARMA GMBH (DE) | 1999-10-28 | — | — | WO | claimed |
| WO-1999031063-A1 | NEW PIPERAZINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | claimed |
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-09-09 | — | — | US | disclosed |
| EP-1079832-B1 | USE OF VITAMIN PP COMPOUNDS | KLINGE CO CHEM PHARM FAB (DE) | 2005-11-30 | — | — | EP | disclosed |
| EP-1060163-B1 | NEW PIPERAZINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | KLINGE CO CHEM PHARM FAB (DE) | 2005-10-12 | — | — | EP | disclosed |
| US-6903118-B1 | Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides | KLINGE PHARMA GMBH (DE) | 2005-06-07 | — | — | US | disclosed |
| EP-1079832-A1 | USE OF VITAMIN PP COMPOUNDS | Klinge Pharma GmbH (DE) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999053920-A1 | USE OF VITAMIN PP COMPOUNDS | KLINGE PHARMA GMBH (DE) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | PNPO, NAMPT, NAPRT | KDM4E 3322/4885HSD17B10 3302/4885ALDH1A1 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.